[Therapeutic decisions and treatment with sorafenib in hepatocellular carcinoma: final analysis of GIDEON study in Italy]

Risultato della ricerca: Contributo in rivistaArticolo in rivista

10 Citazioni (Scopus)

Abstract

Sorafenib, an oral multikinase inhibitor, is the only targeted agent approved for the treatment of patients with hepatocellular carcinoma (HCC) after demonstration to increase overall survival compared to placebo in two randomized phase III study. GIDEON (Global Investigation of therapeutic DEcisions in HCC and Of its treatment with sorafeNib) is the largest, global, non-interventional, prospective study of patients with uHCC (n>3200) treated with sorafenib in real-life clinical practice conditions. Here we report the final analysis of safety and efficacy in the Italian cohort of patients.
Titolo tradotto del contributo[Autom. eng. transl.] [Therapeutic decisions and treatment with sorafenib in hepatocellular carcinoma: final analysis of GIDEON study in Italy]
Lingua originaleItalian
pagine (da-a)217-226
Numero di pagine10
RivistaRecenti Progressi in Medicina
Volume106
DOI
Stato di pubblicazionePubblicato - 2015

Keywords

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents
  • Carcinoma, Hepatocellular
  • Female
  • Humans
  • Italy
  • Liver Neoplasms
  • Male
  • Middle Aged
  • Niacinamide
  • Phenylurea Compounds
  • Prospective Studies

Fingerprint

Entra nei temi di ricerca di '[Therapeutic decisions and treatment with sorafenib in hepatocellular carcinoma: final analysis of GIDEON study in Italy]'. Insieme formano una fingerprint unica.

Cita questo